Diabetes and obesity are the main metabolic drivers of peripheral neuropathy
dc.contributor.author | Callaghan, Brian C. | |
dc.contributor.author | Gao, LeiLi | |
dc.contributor.author | Li, Yufeng | |
dc.contributor.author | Zhou, Xianghai | |
dc.contributor.author | Reynolds, Evan | |
dc.contributor.author | Banerjee, Mousumi | |
dc.contributor.author | Pop‐busui, Rodica | |
dc.contributor.author | Feldman, Eva L. | |
dc.contributor.author | Ji, Linong | |
dc.date.accessioned | 2018-05-15T20:14:05Z | |
dc.date.available | 2019-06-03T15:24:19Z | en |
dc.date.issued | 2018-04 | |
dc.identifier.citation | Callaghan, Brian C.; Gao, LeiLi; Li, Yufeng; Zhou, Xianghai; Reynolds, Evan; Banerjee, Mousumi; Pop‐busui, Rodica ; Feldman, Eva L.; Ji, Linong (2018). "Diabetes and obesity are the main metabolic drivers of peripheral neuropathy." Annals of Clinical and Translational Neurology 5(4): 397-405. | |
dc.identifier.issn | 2328-9503 | |
dc.identifier.issn | 2328-9503 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/143679 | |
dc.description.abstract | ObjectiveTo determine the associations between individual metabolic syndrome (MetS) components and peripheral neuropathy in a large populationâ based cohort from Pinggu, China.MethodsA crossâ sectional, randomly selected, populationâ based survey of participants from Pinggu, China was performed. Metabolic phenotyping and neuropathy outcomes were performed by trained personnel. Glycemic status was defined according to the American Diabetes Association criteria, and the MetS using modified consensus criteria (body mass index instead of waist circumference). The primary peripheral neuropathy outcome was the Michigan Neuropathy Screening Instrument (MNSI) examination. Secondary outcomes were the MNSI questionnaire and monofilament testing. Multivariable models were used to assess for associations between individual MetS components and peripheral neuropathy. Treeâ based methods were used to construct a classifier for peripheral neuropathy using demographics and MetS components.ResultsThe mean (SD) age of the 4002 participants was 51.6 (11.8) and 51.0% were male; 37.2% of the population had normoglycemia, 44.0% prediabetes, and 18.9% diabetes. The prevalence of peripheral neuropathy increased with worsening glycemic status (3.25% in normoglycemia, 6.29% in prediabetes, and 15.12% in diabetes, P < 0.0001). Diabetes (odds ratio [OR] 2.60, 95% CI 1.77â 3.80) and weight (OR 1.09, 95% CI 1.02â 1.18) were significantly associated with peripheral neuropathy. Age, diabetes, and weight were the primary splitters in the classification tree for peripheral neuropathy.InterpretationSimilar to previous studies, diabetes and obesity are the main metabolic drivers of peripheral neuropathy. The consistency of these results reinforces the urgent need for effective interventions that target these metabolic factors to prevent and/or treat peripheral neuropathy. | |
dc.publisher | Wadsworth | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.title | Diabetes and obesity are the main metabolic drivers of peripheral neuropathy | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Neurology and Neurosciences | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/143679/1/acn3531_am.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/143679/2/acn3531.pdf | |
dc.identifier.doi | 10.1002/acn3.531 | |
dc.identifier.source | Annals of Clinical and Translational Neurology | |
dc.identifier.citedreference | Feldman EL, Stevens MJ, Thomas PK, et al. A practical twoâ step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994; 17: 1281 â 1289. | |
dc.identifier.citedreference | Novella SP, Inzucchi SE, Goldstein JM. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve 2001; 24: 1229 â 1231. | |
dc.identifier.citedreference | Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001; 24: 1448 â 1453. | |
dc.identifier.citedreference | Straub RH, Thum M, Hollerbach C, et al. Impact of obesity on neuropathic late complications in NIDDM. Diabetes Care 1994; 17: 1290 â 1294. | |
dc.identifier.citedreference | Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341 â 350. | |
dc.identifier.citedreference | Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009; 35: 206 â 213. | |
dc.identifier.citedreference | Callaghan BC, Xia R, Reynolds E, et al. Association between metabolic syndrome components and polyneuropathy in an obese population. JAMA Neurol 2016; 73: 1468 â 1476. | |
dc.identifier.citedreference | Callaghan BC, Xia R, Banerjee M, et al. Metabolic syndrome components are associated with symptomatic polyneuropathy independent of glycemic status. Diabetes Care 2016; 39: 801 â 807. | |
dc.identifier.citedreference | Lu B, Hu J, Wen J, et al. Determination of peripheral neuropathy prevalence and associated factors in Chinese subjects with diabetes and preâ diabetesâ ShangHai Diabetic neuRopathy Epidemiology and Molecular Genetics Study (SHâ DREAMS). PLoS One 2013; 8: e61053. | |
dc.identifier.citedreference | Han L, Ji L, Chang J, et al. Peripheral neuropathy is associated with insulin resistance independent of metabolic syndrome. Diabetol Metab Syndr 2015; 7: 14. | |
dc.identifier.citedreference | American Diabetes A. 2. Classification and diagnosis of diabetes. Diabetes Care 2017; 40 ( Suppl 1 ): S11 â S24. | |
dc.identifier.citedreference | Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640 â 1645. | |
dc.identifier.citedreference | Breiman L, Friedman JH, Olshen RA, Stone CJ. Classification and regression trees. Belmont, CA: Wadsworth, 1984. | |
dc.identifier.citedreference | Zhang H, Singer B. Recursive partitioning in the health sciences. New York City, NY: Springer, 1999. | |
dc.identifier.citedreference | Hanewinckel R, Drenthen J, Ligthart S, et al. Metabolic syndrome is related to polyneuropathy and impaired peripheral nerve function: a prospective populationâ based cohort study. J Neurol Neurosurg Psychiatry 2016; 87: 1336 â 1342. | |
dc.identifier.citedreference | Lee CC, Perkins BA, Kayaniyil S, et al. Peripheral neuropathy and nerve dysfunction in individuals at high risk for type 2 diabetes: the PROMISE cohort. Diabetes Care 2015; 38: 793 â 800. | |
dc.identifier.citedreference | Ziegler D, Rathmann W, Dickhaus T, et al.; Group KS. Prevalence of polyneuropathy in preâ diabetes and diabetes is associated with abdominal obesity and macroangiopathy: the MONICA/KORA Augsburg Surveys S2 and S3. Diabetes Care 2008; 31: 464 â 469. | |
dc.identifier.citedreference | Gregg EW, Gu Q, Williams D, et al. Prevalence of lower extremity diseases associated with normal glucose levels, impaired fasting glucose, and diabetes among U.S. adults aged 40 or older. Diabetes Res Clin Pract 2007; 77: 485 â 488. | |
dc.identifier.citedreference | Sumner CJ, Sheth S, Griffin JW, et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108 â 111. | |
dc.identifier.citedreference | Knowler WC, Barrettâ Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393 â 403. | |
dc.identifier.citedreference | Hanewinckel R, Drenthen J, van Oijen M, et al. Prevalence of polyneuropathy in the general middleâ aged and elderly population. Neurology 2016; 87: 1892 â 1898. | |
dc.identifier.citedreference | Herman WH, Popâ Busui R, Braffett BH, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med 2012; 29: 937 â 944. | |
dc.identifier.citedreference | Ismailâ Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419 â 430. | |
dc.identifier.citedreference | Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006; 29: 340 â 344. | |
dc.identifier.citedreference | Chronic symmetric symptomatic polyneuropathy in the elderly: a field screening investigation in two Italian regions. I. Prevalence and general characteristics of the sample. Italian General Practitioner Study Group (IGPSG). Neurology 1995; 45: 1832 â 1836. | |
dc.identifier.citedreference | Gregg EW, Sorlie P, Pauloseâ Ram R, et al. Prevalence of lowerâ extremity disease in the US adult population >=40 years of age with and without diabetes: 1999â 2000 National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 1591 â 1597. | |
dc.identifier.citedreference | Popâ Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136 â 154. | |
dc.identifier.citedreference | Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy: a review. JAMA 2015; 314: 2172 â 2181. | |
dc.identifier.citedreference | Davis WA, Norman PE, Bruce DG, Davis TM. Predictors, consequences and costs of diabetesâ related lower extremity amputation complicating type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2006; 49: 2634 â 2641. | |
dc.identifier.citedreference | Callaghan BC, Little AA, Feldman EL, Hughes RA. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; 6: CD007543. | |
dc.identifier.citedreference | Callaghan BC, Kerber KA, Lisabeth LL, et al. Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. JAMA Neurol 2014; 71: 1143 â 1149. | |
dc.identifier.citedreference | Dyck PJ, Oviatt KF, Lambert EH. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol 1981; 10: 222 â 226. | |
dc.identifier.citedreference | Johannsen L, Smith T, Havsager AM, et al. Evaluation of patients with symptoms suggestive of chronic polyneuropathy. J Clin Neuromuscul Dis 2001; 3: 47 â 52. | |
dc.identifier.citedreference | Lubec D, Mullbacher W, Finsterer J, Mamoli B. Diagnostic workâ up in peripheral neuropathy: an analysis of 171 cases. Postgrad Med J 1999; 75: 723 â 727. | |
dc.identifier.citedreference | Bonadonna RC, Cucinotta D, Fedele D, et al. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinicâ based survey. Diabetes Care 2006; 29: 2701 â 2707. | |
dc.identifier.citedreference | Costa LA, Canani LH, Lisboa HR, et al. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabet Med 2004; 21: 252 â 255. | |
dc.identifier.citedreference | Isomaa B, Henricsson M, Almgren P, et al. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001; 44: 1148 â 1154. | |
dc.identifier.citedreference | Ylitalo KR, Sowers M, Heeringa S. Peripheral vascular disease and peripheral neuropathy in individuals with cardiometabolic clustering and obesity: National Health and Nutrition Examination Survey 2001â 2004. Diabetes Care 2011; 34: 1642 â 1647. | |
dc.identifier.citedreference | De Block CE, De Leeuw IH, Van Gaal LF. Impact of overweight on chronic microvascular complications in type 1 diabetic patients. Diabetes Care 2005; 28: 1649 â 1655. | |
dc.identifier.citedreference | Franklin GM, Kahn LB, Baxter J, et al. Sensory neuropathy in nonâ insulinâ dependent diabetes mellitus. The San Luis Valley Diabetes Study. Am J Epidemiol 1990; 131: 633 â 643. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.